Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 9;13(1):852.
doi: 10.1038/s41467-022-28544-w.

Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection

Jing Zou #  1 , Hongjie Xia #  1 , Xuping Xie #  1 , Chaitanya Kurhade  1 , Rafael R G Machado  2 , Scott C Weaver  2   3 , Ping Ren  4 , Pei-Yong Shi  5   6   7   8   9   10
Affiliations

Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection

Jing Zou et al. Nat Commun. .

Abstract

The spread of the Omicron SARS-CoV-2 variant underscores the importance of analyzing the cross-protection from previous non-Omicron infection. We have developed a high-throughput neutralization assay for Omicron SARS-CoV-2 by engineering the Omicron spike gene into an mNeonGreen USA-WA1/2020 SARS-CoV-2 (isolated in January 2020). Using this assay, we determine the neutralization titers (defined as the maximal serum dilution that inhibited 50% of infectious virus) of patient sera collected at 1- or 6-months after infection with non-Omicron SARS-CoV-2. From 1- to 6-month post-infection, the neutralization titers against USA-WA1/2020 decrease from 601 to 142 (a 4.2-fold reduction), while the neutralization titers against Omicron-spike SARS-CoV-2 remain low at 38 and 32, respectively. Thus, at 1- and 6-months after non-Omicron SARS-CoV-2 infection, the neutralization titers against Omicron are 15.8- and 4.4-fold lower than those against USA-WA1/2020, respectively. The low cross-neutralization against Omicron from previous non-Omicron infection supports vaccination of formerly infected individuals to mitigate the health impact of the ongoing Omicron surge.

PubMed Disclaimer

Conflict of interest statement

The authors declare competing interests. X.X. and P.-Y.S. have filed a patent on the reverse genetic system. J.Z., H.X., X.X., and P.-Y.S. received compensation from Pfizer for COVID-19 vaccine development. Other authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Reduced neutralization of Omicron SARS-CoV-2 by previous non-Omicron viral infection.
50% fluorescent focus reduction neutralization titers (FFRNT50) were measured for two serum panels from patients previously infected with non-Omicron SARS-CoV-2. The first serum panel was collected at 1-month post-infection (n = 64) and the second panel collected at 6-months post-infection (n = 36). For each serum, FFRNT50 values were determined against mNG USA-WA1/2020 (in gray color) and Omicron-spike SARS-CoV-2 (in red color). a FFRNT50s of 1-month postinfection sera (shown as circles). b FFRNT50s of 6-month postinfection sera (shown as triangles). Supplementary Tables 1 and 2 summarize the FFRNT50 values and serum information for (a) and (b), respectively. Each symbol of dots (a) and triangles (b) represents one serum specimen. The FFRNT50 value for each serum was determined in duplicate assays and is presented as the geometric mean. The bar heights and the numbers above each set of data indicate geometric mean titers. The whiskers indicate 95% confidence intervals. The dotted line indicates the first serum dilution (1:20) of the FFRNT assay. The FFRNT50 values of sera that did not show any inhibition of viral infection are presented as 10 for plot purposes and statistical analysis. Statistical analysis was performed using the Wilcoxon matched-pairs signed-rank test. The statistical significance of the difference between the geometric mean titers against USA-WA1/2020 and Omicron-spike SARS-CoV-2 is p < 0.0001 in both (a) and (b).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Plante, J. A. et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature, 10.1038/s41586-020-2895-3 (2020). - PMC - PubMed
    1. Xie X, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. 2021;27:620–621. doi: 10.1038/s41591-021-01270-4. - DOI - PubMed
    1. Liu, Y. et al. The N501Y spike substitution enhances SARS-CoV-2 transmission. Nature, In press, 10.1101/2021.03.08.434499 (2021). - PMC - PubMed
    1. WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.... (2021).
    1. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. Technical brief 31 (2021).

Publication types

Supplementary concepts